华润双鹤：公司部分药品拟中选国家组织集采药品接续采购

Core Viewpoint - China Resources Double Crane announced that the company and some subsidiaries participated in the national organized procurement for drugs whose agreements are expiring, with several drugs expected to be selected for procurement [1] Group 1: Selected Drugs and Revenue Impact - The main drugs expected to be selected include: - Valsartan and Hydrochlorothiazide Tablets with projected sales revenue of 517 million yuan, accounting for 4.61% of the 2024 annual revenue [1] - Nifedipine Controlled-Release Tablets with projected sales revenue of 147 million yuan, accounting for 1.31% of the 2024 annual revenue [1] - Enoxaparin Sodium Injection with projected sales revenue of 128 million yuan, accounting for 1.14% of the 2024 annual revenue [1] - Nifedipine Sustained-Release Tablets (II) with projected sales revenue of 118 million yuan, accounting for 1.05% of the 2024 annual revenue [1] - Irbesartan Dispersible Tablets with projected sales revenue of 110 million yuan, accounting for 0.98% of the 2024 annual revenue [1]